5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
+58.74%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$447M
AUM Growth
+$447M
(+18%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-24.1%
Top 10 Holdings %
Top 10 Hldgs %
68.5%
Holding
29
New
4
Increased
4
Reduced
6
Closed
3
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
$20.7M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$14.1M |
| 3 |
SLN
Silence Therapeutics
SLN
|
$10.3M |
| 4 |
Adverum Biotechnologies
ADVM
|
$7.66M |
| 5 |
Tyra Biosciences
TYRA
|
$6.3M |
Top Sells
| 1 |
Q32 Bio
QTTB
|
$73M |
| 2 |
Viking Therapeutics
VKTX
|
$28.5M |
| 3 |
Enliven Therapeutics
ELVN
|
$23.3M |
| 4 |
Disc Medicine
IRON
|
$17M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$11.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enliven Therapeutics
ELVN
$1.2B
| $67.5M | 15.11% | 3,835,975 -1,325,000 | -26% | -$23.3M |
|
2
Entrada Therapeutics
TRDA
$208M
| $62.5M | 13.99% | 4,408,379 | – | – |
|
3
Dianthus Therapeutics
DNTH
$759M
| $37.3M | 8.34% | 1,242,029 -230,235 | -16% | -$6.91M |
|
4
Merus
MRUS
$4.98B
| $24.7M | 5.53% | 548,825 +27,294 | +5% | +$1.23M |
|
5
Celldex Therapeutics
CLDX
$1.47B
| $20.9M | 4.67% | 497,270 | – | – |
|
|
6
Praxis Precision Medicines
PRAX
$958M
| $20.7M | 4.65% | +340,000 | New | +$20.7M |
|
|
7
Viking Therapeutics
VKTX
$3.04B
| $19.5M | 4.36% | 237,560 -347,440 | -59% | -$28.5M |
|
8
Pharvaris
PHVS
$1.39B
| $18.4M | 4.13% | 797,600 | – | – |
|
9
Biohaven
BHVN
$1.63B
| $17.5M | 3.92% | 319,972 -80,000 | -20% | -$4.38M |
|
10
Avidity Biosciences
RNA
$5.99B
| $17M | 3.8% | 665,555 | – | – |
|
|
11
Tyra Biosciences
TYRA
$675M
| $15.4M | 3.45% | 939,298 +384,319 | +69% | +$6.3M |
|
12
Vor Biopharma
VOR
$250M
| $15.1M | 3.38% | 6,361,723 | – | – |
|
13
MoonLake Immunotherapeutics
MLTX
$3.54B
| $14.2M | 3.18% | 282,313 -20,317 | -7% | -$1.02M |
|
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$2.25B
| $14.1M | 3.15% | +1,245,000 | New | +$14.1M |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $12.9M | 2.89% | 736,595 +150,000 | +26% | +$2.63M |
|
|
SLN
16
Silence Therapeutics
SLN
$227M
| $10.3M | 2.3% | +476,200 | New | +$10.3M |
|
17
AnaptysBio
ANAB
$569M
| $8.06M | 1.8% | 357,733 | – | – |
|
18
Zentalis Pharmaceuticals
ZNTL
$122M
| $7.72M | 1.73% | 490,000 | – | – |
|
|
19
Adverum Biotechnologies
ADVM
$64.6M
| $7.66M | 1.71% | +541,666 | New | +$7.66M |
|
20
Rallybio
RLYB
$22.4M
| $6.72M | 1.5% | 3,630,724 | – | – |
|
21
GH Research
GHRS
$837M
| $6.1M | 1.37% | 572,665 +168,261 | +42% | +$1.79M |
|
22
scPharmaceuticals
SCPH
$295M
| $6.03M | 1.35% | 1,200,647 | – | – |
|
23
Mersana Therapeutics
MRSN
$36.5M
| $5.85M | 1.31% | 1,305,000 | – | – |
|
24
Cogent Biosciences
COGT
$1.69B
| $5.31M | 1.19% | 790,440 | – | – |
|
|
25
Q32 Bio
QTTB
$20.9M
| $4.29M | 0.96% | 251,994 -4,283,925 | -94% | -$73M |
|